Grace Therapeutics GRCE
NASDAQ GRCE
$1.93 +0.01 (+0.78%)
At close: Oct 23, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2020 - 2026)

Updated

Grace Therapeutics (GRCE) posted Asset Writedowns and Impairment of $13.53 million for fiscal Q1 2027 (quarter ended Jun 30, 2026).

Analysis

Grace Therapeutics (GRCE) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Asset Writedowns and Impairment at Grace Therapeutics was $13.69 million; for FY2023 (ended Mar 31, 2023), it came in at $28.68 million.

  • In prior fiscal years, Grace Therapeutics' Asset Writedowns and Impairment was $3.71 million in FY2021.
  • The fiscal Q1 2027 figure stands as the lowest quarterly Asset Writedowns and Impairment since fiscal Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Grace Therapeutics 33.33 Mn -32.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.53 Mn
Mar 31, 2024 -32,000.00
Sep 30, 2023 19,000.00
Jun 30, 2023 13,000.00
Mar 31, 2023 28.65 Mn
Sep 30, 2022 31,000.00
Mar 31, 2022 -249,000.00
Mar 31, 2021 -3.71 Mn
Sep 30, 2020 3.71 Mn
API Access

Grace Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=GRCE&period=max&api_key=YOUR_API_KEY